Abstract:Infection with Brucella spp. continues to pose a human health risk globally despite strides in eradicating the disease from domestic animals. Brucellosis has been an emerging disease since the discovery of Brucella melitensis by Sir David Bruce in 1887. Although many countries have eradicated B. abortus from cattle, in some areas B. melitensis and B. suis have emerged as causes of this infection in cattle, leading to human infections. Currently B. melitensis remains the principal cause of human brucellosis worldwide including India. The recent isolation of distinct strains of Brucella from marine mammals as well as humans is an indicator of an emerging zoonotic disease. Brucellosis in endemic and non-endemic regions remains a diagnostic puzzle due to misleading non-specific manifestations and increasing unusual presentations. Fewer than 10% of human cases of brucellosis may be clinically recognized and treated or reported. Routine serological surveillance is not practiced even in Brucella - endemic countries and we suggest that this should be a part of laboratory testing coupled with a high index of clinical suspicion to improve the level of case detection. The screening of family members of index cases of acute brucellosis in an endemic area should be undertaken to pick up additional unrecognised cases. Rapid and reliable, sensitive and specific, easy to perform and automated detection systems for Brucella spp. are urgently needed to allow early diagnosis and adequate antibiotic therapy in time to decrease morbidity / mortality. The history of travel to endemic countries along with exposure to animals and exotic foods are usually critical to making the clinical diagnosis. Laboratory testing is indispensable for diagnosis. Therefore alertness of clinician and close collaboration with microbiologist are essential even in endemic areas to correctly diagnose and treat this protean human infection. Existing treatment options, largely based on experience gained > 30 years ago, are adequate but not optimal. In our experience, an initial combination therapy with a three drug-regimen followed by a two-drug regimen for at least six weeks and a combination of two drugs with a minimum of six weeks seems warranted to improve outcome in children and adult patients respectively with laboratory monitoring. A safe and effective vaccine in humans is not yet available. Prevention is dependent upon the control of the disease in animal hosts, effective heat treatment of dairy produce and hygienic precautions to prevent occupational exposure. This review compiles the experiences and diagnostic and treatment paradigms currently employed in fighting this disease.

Lessons learned from dealing with the challenge of canine brucellosis in practice

The emergence of Brucella canis as a public health threat in Europe: what we know and what we need to learn

Transmission of Brucella canis in a canine kennel following introduction of an infected dog

Antibody response over time correlated with treatment outcome in 30 dogs naturally infected with Brucella canis (2017-2022)

Human exposures to Brucella canis from a pregnant dog during an international flight: Public health risks, diagnostic challenges and future considerations

A one-health review on brucellosis in the United States

Canine Brucellosis: An Update

The changing Brucella ecology: novel reservoirs, new threats

Brucellosis and One Health: Inherited and Future Challenges

Analysis of exotic pathogens found in a large group of imported dogs following an animal welfare investigation

Brucellosis: epidemiology, pathogenesis, diagnosis and treatment–a comprehensive review

Proteomics and bioinformatics investigations to improve serological diagnosis of canine brucellosis

Brucella suis in three dogs: presentation, diagnosis and clinical management

The many faces of brucellosis: diagnostic and management approach

Imported brucellosis: A case series and literature review

One health approach to tackle brucellosis: a systematic review

Bovine brucellosis – a comprehensive review

Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis

Evaluation of Three Serological Tests for Diagnosis of Canine Brucellosis

Review of clinical and laboratory features of human brucellosis

Brucellae as resilient intracellular pathogens: epidemiology, host–pathogen interaction, recent genomics and proteomics approaches, and future perspectives